The agonist is called a "primary mover" or the working muscle contracting during a movement, while the antagonist is the ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

KOLs interviewed by GlobalData and surveyed prescribing physicians agreed that there is a gap in the market for safer ...

BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel ...

Perceptual inference requires the integration of visual features through recurrent processing, the dynamic exchange of information between higher and lower level cortical regions. While animal ...

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

By Hugo Francisco de Souza New research reveals that liraglutide, a GLP-1 receptor agonist, crosses the blood-brain barrier ...

Omass Therapeutics Ltd. has identified compounds acting as melanocortin MC2 receptor antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, Cushing syndrome, depression ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

The leading Toll-Like Receptor 4 (TLR-4) Agonist Companies such as Eisai, Akaza Bioscience, OPNT-003, GeNeuro, MN-166 ...